Clinical Outcome with Oral Linezolid and Rifampin Following Recurrent Methicillin-Resistant Staphylococcus aureus Bacteremia Despite Prolonged Vancomycin Treatment
Drug-resistant Gram-positive bacteria, especially Staphylococcus aureus, are emerging as the predominant organisms involved in both nosocomial and community-acquired infections. Since the 1980s, vancomycin has been the first-line antibiotic used to treat methicillin-resistant S aureus. However, alle...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2004-01-01
|
| Series: | Canadian Journal of Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/2004/768765 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553038394425344 |
|---|---|
| author | Jon-David Schwalm Philippe El-Helou Christine H Lee |
| author_facet | Jon-David Schwalm Philippe El-Helou Christine H Lee |
| author_sort | Jon-David Schwalm |
| collection | DOAJ |
| description | Drug-resistant Gram-positive bacteria, especially Staphylococcus aureus, are emerging as the predominant organisms involved in both nosocomial and community-acquired infections. Since the 1980s, vancomycin has been the first-line antibiotic used to treat methicillin-resistant S aureus. However, allergy and intolerance to vancomycin, the increasing number of vancomycin clinical failures and the existence of vancomycin intermediate-susceptible isolates of S aureus suggest that new antibiotics are needed. This paper reports the only known case of a successful clinical outcome with long term oral linezolid and rifampin therapy in the management of recurrent and persistent methicillin-resistant S aureus bacteremia with metastatic infections despite prolonged vancomycin use. More than two years since the initiation of linezolid and rifampin, the study patient has been clinically well with no evidence of adverse drug reactions including cytopenia and hepatic toxicities. Physicians must be aware of the novel developments in antibiotic therapy to treat drug-resistant bacterial infections. |
| format | Article |
| id | doaj-art-1ff874edab834193aed5c49d22c2857a |
| institution | Kabale University |
| issn | 1180-2332 |
| language | English |
| publishDate | 2004-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases |
| spelling | doaj-art-1ff874edab834193aed5c49d22c2857a2025-02-03T05:57:07ZengWileyCanadian Journal of Infectious Diseases1180-23322004-01-011529710010.1155/2004/768765Clinical Outcome with Oral Linezolid and Rifampin Following Recurrent Methicillin-Resistant Staphylococcus aureus Bacteremia Despite Prolonged Vancomycin TreatmentJon-David Schwalm0Philippe El-Helou1Christine H Lee2Department of Medicine, McMaster University, Hamilton, Ontario, CanadaDepartment of Medicine, McMaster University, Hamilton, Ontario, CanadaDepartment of Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, CanadaDrug-resistant Gram-positive bacteria, especially Staphylococcus aureus, are emerging as the predominant organisms involved in both nosocomial and community-acquired infections. Since the 1980s, vancomycin has been the first-line antibiotic used to treat methicillin-resistant S aureus. However, allergy and intolerance to vancomycin, the increasing number of vancomycin clinical failures and the existence of vancomycin intermediate-susceptible isolates of S aureus suggest that new antibiotics are needed. This paper reports the only known case of a successful clinical outcome with long term oral linezolid and rifampin therapy in the management of recurrent and persistent methicillin-resistant S aureus bacteremia with metastatic infections despite prolonged vancomycin use. More than two years since the initiation of linezolid and rifampin, the study patient has been clinically well with no evidence of adverse drug reactions including cytopenia and hepatic toxicities. Physicians must be aware of the novel developments in antibiotic therapy to treat drug-resistant bacterial infections.http://dx.doi.org/10.1155/2004/768765 |
| spellingShingle | Jon-David Schwalm Philippe El-Helou Christine H Lee Clinical Outcome with Oral Linezolid and Rifampin Following Recurrent Methicillin-Resistant Staphylococcus aureus Bacteremia Despite Prolonged Vancomycin Treatment Canadian Journal of Infectious Diseases |
| title | Clinical Outcome with Oral Linezolid and Rifampin Following Recurrent Methicillin-Resistant Staphylococcus aureus Bacteremia Despite Prolonged Vancomycin Treatment |
| title_full | Clinical Outcome with Oral Linezolid and Rifampin Following Recurrent Methicillin-Resistant Staphylococcus aureus Bacteremia Despite Prolonged Vancomycin Treatment |
| title_fullStr | Clinical Outcome with Oral Linezolid and Rifampin Following Recurrent Methicillin-Resistant Staphylococcus aureus Bacteremia Despite Prolonged Vancomycin Treatment |
| title_full_unstemmed | Clinical Outcome with Oral Linezolid and Rifampin Following Recurrent Methicillin-Resistant Staphylococcus aureus Bacteremia Despite Prolonged Vancomycin Treatment |
| title_short | Clinical Outcome with Oral Linezolid and Rifampin Following Recurrent Methicillin-Resistant Staphylococcus aureus Bacteremia Despite Prolonged Vancomycin Treatment |
| title_sort | clinical outcome with oral linezolid and rifampin following recurrent methicillin resistant staphylococcus aureus bacteremia despite prolonged vancomycin treatment |
| url | http://dx.doi.org/10.1155/2004/768765 |
| work_keys_str_mv | AT jondavidschwalm clinicaloutcomewithorallinezolidandrifampinfollowingrecurrentmethicillinresistantstaphylococcusaureusbacteremiadespiteprolongedvancomycintreatment AT philippeelhelou clinicaloutcomewithorallinezolidandrifampinfollowingrecurrentmethicillinresistantstaphylococcusaureusbacteremiadespiteprolongedvancomycintreatment AT christinehlee clinicaloutcomewithorallinezolidandrifampinfollowingrecurrentmethicillinresistantstaphylococcusaureusbacteremiadespiteprolongedvancomycintreatment |